 |
|
Blood pressure compound may benefit brain tumor patients
February 18, 2009WINSTON-SALEM, N.C. - A widely used blood pressure medication may be the key to preventing brain function loss common after radiation treatment, according to a newly published study by researchers at Wake Forest University Baptist Medical Center. The findings offer the hope of an improved quality of life for cancer patients.
Using a rat model, the study drew on a hypothesis from previous studies that a compound similar to the anti-hypertensive drug losartan can prevent the cognition loss that has been closely-associated with radiation therapy for brain tumor treatment.
The findings, recently published in the International Journal of Radiation Oncology, Biology, Physics, appear to validate the hypothesis in rats and researchers are optimistic that the same theory could easily be applied in a human clinical trial setting because the drug used has a long-established safety profile in patients who have taken it to treat high blood pressure.
"We need to kill cancer cells but also prevent or reduce treatment-related side effects," said Mike E. Robbins, Ph.D., a professor in the department of radiation oncology at the Brain Tumor Center of Excellence, part of Wake Forest University School of Medicine. "One very interesting feature of this compound is that it has never shown any pro-tumor effects. If anything, it appears to have anti-tumor properties. We're very close to having a compound that will protect the normal brain from cognitive injury as a result of radiation and, at the same time, we may very well increase the likelihood of one day curing brain cancer patients of their tumors."
Researchers have theorized from previous studies that radiation may lead to the overproduction of angiotensin II (Ang II), a peptide that has been associated with decline of brain function. By blocking the binding of Ang II to the Ang type I receptor in patients receiving radiation, researchers hypothesized that they could prevent or hinder cognitive decline. Anti-hypertensive drugs, such as losartan, have been effective in preventing or minimizing radiation-induced injury in the lungs and kidneys, Robbins said, so testing them in the brain was an obvious next step.
The study involved three groups of 80 rats. Each group was divided in half to either receive radiation or no treatment. Then, each of those halves was divided into two more groups: one that received L-158,809, the compound similar to losartan, in its drinking water, and one group that received plain drinking water. The rats that received the drug received it before, during and for different time intervals - 14, 28 or 54 weeks - post-radiation.
In addition, a small group of rats continued to receive the drug for only five weeks after radiation.
Researchers found that administering L-158,809 before, during and for as little as five weeks after radiation either prevents or lessens the severity of radiation-induced cognitive impairment.
"The extent of cognitive impairment experienced by patients who undergo radiation therapy varies in terms of how it is recognized," Robbins said. "Sometimes the patient realizes that their short-term memory is fading or that they've lost the ability to multi-task. Instead of waking up in the morning and having a clear idea of what needs to get done that day, patients finds themselves having to write things down. They just can't keep thoughts in their brain. Sometimes it's a friend or partner that realizes the impairment, but once it is noticed, it is not going to improve. Cognitive decline resulting from radiation is not stable. It is a chronic, progressive condition."
An estimated 170,000 patients undergo radiation therapy annually to treat primary or metastatic brain tumors. At least 50 percent of adult patients who undergo the treatment and live six months or more post-radiation experience some level of cognitive decline. In children, the effect is even greater, Robbins said. "All will have some form of cognitive impairment if they are long-term survivors and, thankfully, with today's technology, most children will survive long-term.
"This study provides hope that we may be able to take a drug that has been prescribed to millions of individuals with essentially very little morbidity and give it to cancer patients and stop them from experiencing cognitive impairment as a result of brain radiation. These drugs are routinely prescribed for the treatment of hypertension, are well-tolerated and exhibit anti-tumor effects," Robbins said. "They appear to be ideal for future clinical trials because they offer the promise of improving the quality of life for brain tumor patients."
Wake Forest University Baptist Medical Center
"We need to kill cancer cells but also prevent or reduce treatment-related side effects," said Mike E. Robbins, Ph.D., a professor in the department of radiation oncology at the Brain Tumor Center of Excellence, part of Wake Forest University School of Medicine. "One very interesting feature of this compound is that it has never shown any pro-tumor effects. If anything, it appears to have anti-tumor properties. We're very close to having a compound that will protect the normal brain from cognitive injury as a result of radiation and, at the same time, we may very well increase the likelihood of one day curing brain cancer patients of their tumors."
Researchers have theorized from previous studies that radiation may lead to the overproduction of angiotensin II (Ang II), a peptide that has been associated with decline of brain function. By blocking the binding of Ang II to the Ang type I receptor in patients receiving radiation, researchers hypothesized that they could prevent or hinder cognitive decline. Anti-hypertensive drugs, such as losartan, have been effective in preventing or minimizing radiation-induced injury in the lungs and kidneys, Robbins said, so testing them in the brain was an obvious next step.
The study involved three groups of 80 rats. Each group was divided in half to either receive radiation or no treatment. Then, each of those halves was divided into two more groups: one that received L-158,809, the compound similar to losartan, in its drinking water, and one group that received plain drinking water. The rats that received the drug received it before, during and for different time intervals - 14, 28 or 54 weeks - post-radiation.
In addition, a small group of rats continued to receive the drug for only five weeks after radiation.
Researchers found that administering L-158,809 before, during and for as little as five weeks after radiation either prevents or lessens the severity of radiation-induced cognitive impairment.
"The extent of cognitive impairment experienced by patients who undergo radiation therapy varies in terms of how it is recognized," Robbins said. "Sometimes the patient realizes that their short-term memory is fading or that they've lost the ability to multi-task. Instead of waking up in the morning and having a clear idea of what needs to get done that day, patients finds themselves having to write things down. They just can't keep thoughts in their brain. Sometimes it's a friend or partner that realizes the impairment, but once it is noticed, it is not going to improve. Cognitive decline resulting from radiation is not stable. It is a chronic, progressive condition."
An estimated 170,000 patients undergo radiation therapy annually to treat primary or metastatic brain tumors. At least 50 percent of adult patients who undergo the treatment and live six months or more post-radiation experience some level of cognitive decline. In children, the effect is even greater, Robbins said. "All will have some form of cognitive impairment if they are long-term survivors and, thankfully, with today's technology, most children will survive long-term.
"This study provides hope that we may be able to take a drug that has been prescribed to millions of individuals with essentially very little morbidity and give it to cancer patients and stop them from experiencing cognitive impairment as a result of brain radiation. These drugs are routinely prescribed for the treatment of hypertension, are well-tolerated and exhibit anti-tumor effects," Robbins said. "They appear to be ideal for future clinical trials because they offer the promise of improving the quality of life for brain tumor patients."
Wake Forest University Baptist Medical Center
Brain Tumor Current Events and Brain Tumor News RSSCancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.
Barrow study identifies new way to biopsy brain tumors in real time
A new miniature, hand-held microscope may allow more precise removal of brain tumors and an easier recognition of tumor locations during surgery.
Men leave: Separation and divorce far more common when the wife is the patient
A woman is six times more likely to be separated or divorced soon after a diagnosis of cancer or multiple sclerosis than if a man in the relationship is the patient, according to a study that examined the role gender played in so-called "partner abandonment." The study also found that the longer the marriage the more likely it would remain intact.
Childhood cancer survivors less likely to marry, Yale researchers find
Adult survivors of childhood cancer are 20 to 25 percent more likely to never marry compared with siblings and the general population, Yale School of Medicine researchers report in a new study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Brain tumors in childhood leave a lasting mark on cognition, life status
Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems.
Angiochem crosses BBB, shows safety, efficacy in phase 1/2 brain cancer studies
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.
Researchers report benefits of new standard treatment study for rare pediatric brain cancer
A team of researchers led by The University of Texas M. D. Anderson Cancer Center unveiled results today from the largest-ever collaborative study addressing the treatment of a rare pediatric brain tumor.
Unequal access: Hispanic children rarely get top-notch care for brain tumors
Hispanic children diagnosed with brain tumors get high-quality treatment at hospitals that specialize in neurosurgery far less often than other children with the same condition, potentially compromising their immediate prognosis and long-term survival, according to research from Johns Hopkins published in October's Pediatrics.
tudy: The new buzz on detecting tinnitus
It's a ringing, a buzzing, a hissing or a clicking - and the patient is the only one who can hear it. Complicating matters, physicians can rarely pinpoint the source of tinnitus, a chronic ringing of the head or ears that can be as quiet as a whisper or as loud as a jackhammer.
New Approach for the Treatment of Malignant Brain Tumors
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence.
More Brain Tumor Current Events and Brain Tumor News Articles
 |
Living with a Brain Tumor: Dr. Peter Black's Guide to Taking Control of Your Treatment by Peter Black (Author) Each year, 100,000 people in the United States are diagnosed with a brain tumor. With his new book, Dr. Peter Black fills a gap in the lay readership, providing an accessible medical resource for adult patients and their families. Dr. Black, who has operated on more than 3,000 patients with brain tumors, is uniquely qualified to discuss both clinical treatment of and research into brain tumors. This invaluable resource tells patients everything they need to know to understand and address their diagnosis, in a four-part structure: • “What is a Brain Tumor?" provides straightforward information about how brain tumors are diagnosed, the different types of tumors and how they develop, and where to go for treatment. • “Coping with Shock” addresses the emotional... |
 |
Curveball: When Life Throws You a Brain Tumor by Liz Holzemer (Author) Life seemed idyllic for thirty-two-year-old Liz Holzemer. Wife of Major League Baseball pitcher Mark Holzemer, Liz was enjoying a successful career as a journalist when an MRI revealed a baseball-size brain tumor she soon found out was called meningioma. Told with clarity and unwavering humor, this book is an inspirational and informative account of one woman’s battle for her life. It shows how she emerged from this frightening diagnosis and two brain surgeries retaining her remarkable spirit of survival and renewed sense of purpose and hope. With practical information about meningioma and brain surgery, Curveball is a manual for people who face life-altering challenges and is also proof that one need not fight such battles alone. |
 |
Guerilla Guide to Brain Tumors: Shameless Dirty Tricks to beat the system and STAY ALIVE! by Skip Goebel (Author) In an unprecedented format, the Guerilla Guide to Brain Tumors is written in a format that combines the layout of the For Dummies series with a drill-sargent's attitude. (the back page says it all) This is a book of War Nothing warm and fuzzy or socially acceptable here and nothing about "Dying with Dignity". Just what it takes to win. And win you will, complete with a trail of wreckage behind you. It's a book for the patient, NOT the caregiver. The Guerilla Guide to Brain Tumors is a book that will take you out of the "Grovel and Wretch" mode and into the "Command and Dominate" mode with the following factions of our society: The Medical EstablishmentThe Social Services EstablishmentChurch, Friends and FamilyAnd most importantly...Yourself No punches are pulled here. Prepare to be... |
 |
Damn The Statistics, I Have a Life to Live!: Coping with a Brain Tumor My Personal Story by Harry Wolf (Author) June 3, 2002 was the day that changed my life forever. A 43-year-old father of three, whom in oneday went from being a successful senior manager to a man with a braintumor. I have a glioblastoma multiformegrade IV brain tumor, the most deadly and aggressive type of brain tumor. This book covers how I have dealt with lifeafter being informed that I have a tumor that only 1-2% survive for 2years. I share the experiences, thoughts,and events from my first year as a survivor. When I was first diagnosed, I searched for a book that covered thedetails of what could be expected on both a medical and personal level. I could not find, so I wrote one. I maintained a detailed journal. I cover the first surgery, an awakecraniotomy, and the subsequent head infection that led to a second... |
 |
Brain Tumors: Leaving the Garden of Eden--A Survival Guide to Diagnosis, Learning the Basics, Getting Organized, and Finding Your Medical Team by Paul M. Zeltzer (Author) A guidebook for the 150,000+ people/ year and families affected by brain tumors. This book will help you learn the basics about diagnosis, getting organized and finding your medical team. Included are chapters on all major types of brain tumors & metastases, glossary, medications, using the Internet to search for information, and getting a second opinion. "Brain Tumors:Leaving the Garden of Eden" is all about improving your odds by gathering information, & assessing your situation: What you need to do; what you need to know; what you can do now! |
 |
Searching for Normal, My Life with a Brain Tumor by Mikki Baker (Author) This is a simple and true story of a young nurse, wife and mother of three, leading a typical American middle-class life, until one day in April 2003. It is a deeply personal and detailed account from Mikki Baker, of how a grand mal seizure on Easter Monday led to the discovery of a large brain tumor, and sent her life and the lives of her family into initial chaos, and how it forever changed the course of the daily existence. The story follows the events from the day of the seizure through the first four-and-a-half years of recovery following the surgery, with the day-to-day details drawn from a journal started by family members. It is a reflection of many of the procedures, problems and emotions that brain tumor patients encounter. The reader will see how very gradual the recovery... |
 |
100 Q&A About Brain Tumors (100 Questions & Answers) by Virginia Stark-Vance (Author) Consumer text provides authoritative, practical answers to questions regarding treatment options, post-treatment quality of life, and sources of support. Co-authored by a brain-tumor survivor, text explains what to expect after the diagnosis and the treatment of a brain tumor. Softcover. |
 |
Brain Surgeon: A Doctor's Inspiring Encounters with Mortality and Miracles by Keith Black (Author), Arnold Mann (Author) Welcome to tiger country: the treacherous territory where a single wrong move by a brain surgeon can devastate-or end-a patient's life. This is the terrain world-renowned neurosurgeon Keith Black, MD, enters every day to produce virtual medical miracles. Now, in BRAIN SURGEON, Dr. Black invites readers to shadow his breathtaking journeys into the brain as he battles some of the deadliest and most feared tumors known to medical science. Along the way, he shares his unique insights about the inner workings of the brain, his unwavering optimism for the future of medicine, and the extraordinary stories of his patients-from ministers and rock stars to wealthy entrepreneurs and uninsured students-whom he celebrates as the real heroes. BRAIN SURGEON offers a window into one man's... |
 |
Brain Tumors (Diseases and Disorders) by Arda Darakjian Clark (Author) Brain tumors, both benign and malignant, present severe challenges to patients, their families, and to the medical professionals who treat them. This book discusses symptoms and diagnosis of brain tumors, standard and experimental treatments, and the need for care and rehabilitation following treatment. (20051001) |
 |
Brain Tumors: Finding the Ark. Meeting the Challenges of Treatment Choices, Side Effects, Childrens Issues, Healthcare Costs and Long Term adjustment by Paul M. Zeltzer (Author) In this sequel to Brain Tumors: Leaving the Garden of Eden, Dr. Paul continues to guide you through the brain tumor minefield so you have the best chances for quality survival. Here are the key answers to questions about medications, side effects and late effects of treatment, insurance, Medicare & HMOs, clinical trials, heredity, brain tumors in children, Complementary and Alternative Medicines & Lists of 250 major brain tumor treatment centers worldwide (30 blk-and-white illustrations , 350 websites and other resources to contact.) |
| © 2009 BrightSurf.com |